托利德通过阻断Nrf2表达来抑制结直肠癌细胞的增殖和侵入
Hui-Feng Wang1, Zhi-Long Zhao1
1The Second General Surgery Department, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Chemical biology & drug design
|January 17, 2024
概括
三胺 (TPL) 有效地抑制结肠直肠癌 (CRC) 细胞的增殖和侵入,同时促进细胞亡. 它的机制涉及向下调节核因子-红素2相关因子2 (Nrf2) 信号,影响MMP-2和MMP-9的表达.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 来自Tripterygium wilfordii的Triptolide (TPL) 具有抗炎症,免疫调节和抗瘤的特性.
- 在各种瘤中,TPL已显示出抑制癌细胞增殖,转移和诱导亡的潜力,包括结直肠癌 (CRC).
- 在TPL的抗CRC作用的基础上,精确的分子机制仍然不完全理解.
研究的目的:
- 在体外研究TPL对人类结直肠癌 (HT29) 细胞的增殖和侵入的影响.
- 阐明TPL在CRC中发挥抗癌作用的分子机制.
- 确定核因子-红色素2相关因子2 (Nrf2) 信号在TPL针对CRC的行动中的作用.
主要方法:
- 用不同度的TPL (0-100nmol/L) 处理HT29细胞.
- 分别使用MTT测定,Transwell测定和流式细胞计量来评估细胞增殖,入侵和细胞亡.
- 分析了Nrf2,MMP-2和MMP-9的蛋白质表达,通过西方涂抹,Nrf2通过sh-Nrf2进一步沉默.
主要成果:
- 在剂量取决的方式上,TPL显著抑制HT29细胞的增殖和侵入.
- 在HT29细胞中,TPL治疗显著促进了细胞亡,在较高度时效应加剧.
- 抑制Nrf2表达进一步增强了TPL对增殖和入侵的抑制作用,并促进了亡,同时降低了MMP-2和MMP-9水平.
结论:
- TPL在抑制结肠直肠癌细胞增殖和侵入方面表现出显著的有效性,同时促进细胞亡.
- 在CRC中TPL的抗癌机制似乎通过抑制Nrf2信号通路进行介导.
- 向Nrf2通路代表了一种潜在的治疗策略,可以提高TPL对结直肠癌的有效性.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
1.6K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.3K
相关概念视频
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K